Monoclonal Antibody Treatment
Roll-out of Monoclonal Antibody Treatment is forthcoming. Medication Kits are being distributed to acute sites. Final Standard orders for Southern Health-Santé Sud is expected by Thursday, December 23 - sites are to use the draft forms until then.
- Memo - Monoclonal Antibody Treatment for COVID-19
- Referral Form
- Monoclonal Antibody Infusion Algorithm
- Standard orders
- Drug Monograph
- Preparation procedure - Casirivimab-Imdevimab
Leads/Directors (or delegates) review and share accordingly.
Updated Clinical Practice Guidelines and COVID-19 mRNA Vaccine Fact Sheet
Please be advised of the following updated COVID-19 vaccine resources for providers and the public:
- Manitoba COVID-19 Vaccine: Clinical Practice Guidelines for Immunizers and Health Care Providers (Version 24; Updated December 20, 2021). Summary of notable changes:
- Updated “guidance for use in special populations for all authorized COVID-19 vaccines used in Manitoba” by removing the requirement of immunizers/health care providers to have additional discussions about the benefits/risks with clients/patients who are pregnant and/or breastfeeding, in light of evolving evidence and recommendations.
- Updated “guidance for use of the viral vector vaccine” to include two additional rare risks (immune thrombocytopenia and venous thromboembolism) following immunization.
- Updated “guidance for use of the mRNA vaccines in the primary series for the adolescent/adult population” aged ≥ 12 years, specifically with respect to the sections on interchangeability and recommended interval, with clarifications to the sections on dosage and guidance for immunocompromised populations. Guidance on timing of vaccine administration following monoclonal antibody treatment has been added.
- Updated “guidance for use of the mRNA vaccine in the pediatric population,” specifically with respect to the recommended interval for the primary series and guidance for children who are immunocompromised.
- COVID-19 mRNA Vaccines Factsheet for Individuals Aged 12 Years and Older (Pfizer/Comirnaty™ and Moderna/Spikevax™) (Updated December 14, 2021).
The COVID-19 Vaccine Consent Form is under review and is anticipated to be updated/posted to the website in the coming days.
Leads/Directors (or delegates) review and share accordingly.
Info Sharing
Media Release
